Medios (OTC:MEDOF) Stock, Quote.Headers.trade-ideas

Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes provision of medicinal products which focuses on pharmaceutical medicinal products; Patient-specific therapies comprise the manufacture of medications.

Medios AG

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $89 to $97.

News

Price Target

Analyst Ratings

MRUS

Citigroup Maintains Buy on Merus, Raises Price Target to $97

Citigroup analyst Michael Bilerman maintains SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) with a Neutral and lowers the price target from $18 to $16.

SITC

Citigroup Maintains Neutral on SITE Centers, Lowers Price Target to $16

UBS analyst Leonardo Olmos downgrades TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) from Buy to Neutral.

Downgrades

TIMB

UBS Downgrades TIM to Neutral

UBS analyst Jay Sole maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and lowers the price target from $82 to $80.

UBS Maintains Neutral on Nike, Lowers Price Target to $80

UBS initiates coverage on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Neutral rating and announces Price Target of $196.

Initiation

UBS Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $196

UBS analyst Josh Silverstein maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Buy and lowers the price target from $168 to $161.

CHRD

UBS Maintains Buy on Chord Energy, Lowers Price Target to $161

UBS analyst Erika Najarian maintains Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) with a Buy and raises the price target from $69 to $85.

UBS Maintains Buy on Wells Fargo, Raises Price Target to $85

UBS analyst Josh Silverstein maintains Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) with a Neutral and raises the price target from $31 to $35.

UBS Maintains Neutral on Antero Resources, Raises Price Target to $35

UBS analyst Josh Silverstein maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Neutral and lowers the price target from $58 to $51.

UBS Maintains Neutral on Occidental Petroleum, Lowers Price Target to $51

UBS analyst Josh Silverstein maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Neutral and lowers the price target from $38 to $34.

UBS Maintains Neutral on Murphy Oil, Lowers Price Target to $34

UBS analyst Josh Silverstein maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and lowers the price target from $28 to $27.

UBS Maintains Neutral on APA, Lowers Price Target to $27

UBS analyst Josh Silverstein maintains Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) with a Buy and lowers the price target from $59 to $56.

UBS Maintains Buy on Ovintiv, Lowers Price Target to $56

UBS analyst Josh Silverstein maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Buy and lowers the price target from $235 to $212.

FANG

UBS Maintains Buy on Diamondback Energy, Lowers Price Target to $212

UBS analyst Josh Silverstein downgrades Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Buy to Neutral and lowers the price target from $36 to $34.

UBS Downgrades Halliburton to Neutral, Lowers Price Target to $34

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

UBS analyst Josh Silverstein upgrades Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Sell to Neutral and raises the price target from $28 to $35.

Upgrades

UBS Upgrades Range Resources to Neutral, Raises Price Target to $35

UBS analyst Josh Silverstein upgrades Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) from Neutral to Buy and raises the price target from $94 to $123.

UBS Upgrades Expand Energy to Buy, Raises Price Target to $123

UBS analyst Joshua Chan maintains Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) with a Buy and raises the price target from $525 to $575.

UBS Maintains Buy on Comfort Systems USA, Raises Price Target to $575

New Lake Capital Partners (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>), a real estate company focused on cannabis properties, offers an attractive investment with a 9.1% dividend yield, well above the return on 10-year government bonds.
This yield, combined with a cautious approach to debt and disciplined portfolio growth, positions NLCP as an attractive alternative to other cannabis REITs like IIPR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) and broader industrial REITs. Trading near par value, NLCP's conservative strategy highlights its potential for stable, long-term returns, as noted by Pablo Zuanic of <a href="https://zuanicgroup.com/">Zuanic &amp; Associates</a>.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Attractive Valuation And Dividend Yield</h3>
One of NLCP's standout features is its 9.1% dividend yield, which is almost 500 basis points (bp) higher than 10-year Treasury bills—the benchmark for low-risk investments.&nbsp;
By comparison, IIPR offers a 6.7% dividend yield but trades at a 57% premium to book value, while NLCP trades at par, reflecting a more conservative approach to valuation.&nbsp;
Zuanic notes this discrepancy &#8211; partly due to IIPR&#8217;s NYSE listing versus NLCP&#8217;s OTC market status -suggests NLCP may be undervalued, with the potential for its valuation to increase as its market recognition grows.
The company's dividend coverage stands at 120%, demonstrating the sustainability of its payouts. NLCP's rental yield is approximately 13%, which,<a href="https://www.benzinga.com/topic/pablo-zuanic"> according to Zuanic</a>, is notably higher than its debt cost of 5.65%, ensuring that it generates sufficient income to cover its dividends.&nbsp;
Read Also: <a href="https://www.benzinga.com/24/12/42340604/better-than-the-bank-weed-real-estate-investment-companys-14-yield-beats-traditional-savings">Better Than The Bank: Weed Real Estate Investment Company&#8217;s 14% Yield Beats Traditional Savings</a>
<h3 class="wp-block-heading">Prudent Portfolio Management And Growth</h3>
NLCP operates with a low debt-to-equity ratio of less than 2%, maintaining an unleveraged balance sheet. This strategy underscores its cautious approach to capital management, particularly in an industry prone to higher volatility.
As of September 2024, NLCP's portfolio consists of 32 properties—including 17 dispensaries and 15 cultivation facilities—spread across 12 states. Zuanic noted these properties are fully rented, with an average lease term of 13.8 years, ensuring long-term income stability.&nbsp;
The company has demonstrated growth, with a 4% increase in its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40834708/new-laws-could-unleash-1-7b-demand-for-cannabis-loans-this-real-estate-stock-is-set">real estate book</a> year-to-date, funded by $2.6 million in new investments in Q3 2024.&nbsp;
This growth rate <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40867279/12m-in-rental-income-why-investors-should-watch-this-stock-thats-crushing-averages">outpaces IIPR</a>, which reported only 2% growth over the same period.
<h3 class="wp-block-heading">Challenges With Tenants And Lease Amendments</h3>
Like any investment, NLCP has faced challenges with a few tenants. Revolutionary Clinics in Massachusetts and Calypso Enterprises in Pennsylvania have struggled with rent payments. The company has amended leases with these tenants and utilized escrow deposits to address rent shortfalls.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42344916/you-are-missing-out-on-this-nasdaq-listed-weed-stock-low-cost-model-meets-european-demand"> Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand</a>
<h3 class="wp-block-heading">Growth Outlook And Acquisition Strategy</h3>
&nbsp;As recreational cannabis markets expand in states like <a href="https://www.benzinga.com/topic/new-york-cannabis">New York</a>, <a href="https://www.benzinga.com/topic/new-jersey-cannabis">New Jersey</a>, <a href="https://www.benzinga.com/topic/ohio-cannabis">Ohio</a>, and <a href="https://www.benzinga.com/topic/connecticut-cannabis">Connecticut</a>, NLCP is positioned for growth. Furthermore, large medical markets such as <a href="https://www.benzinga.com/topic/pennsylvania-cannabis">Pennsylvania</a> and <a href="https://www.benzinga.com/topic/virginia-cannabis">Virginia</a> could transition to recreational sales within the next two years, creating new growth opportunities.
In 2024, NLCP made a $4 million acquisition of a cultivation facility in Connecticut (C3 Industries), with $12 million committed to building improvements. As of September 2024, the company has $21.2 million in construction-in-progress, primarily in <a href="https://www.benzinga.com/topic/arizona-cannabis">Arizona</a> and Connecticut, indicating continued expansion of its portfolio.
<h3 class="wp-block-heading">Stock Performance And Sector Comparison</h3>
Over the past 90 days, NLCP's stock has been relatively stable, down 3%, compared to the broader <a href="https://www.benzinga.com/markets/cannabis/24/10/41214215/cannabis-focused-commercial-mortgage-reit-exceeds-100m-in-new-originations-with-41m-credit-facil">industrial REIT </a>sector, which declined 13%.&nbsp;
NLCP trades at par, with a book value per share (BVPS) of $19.48 as of Q3 2024, well below the 57% premium at which IIPR trades. According to Zuanic, NLCP's stock is priced close to its actual value of $19.48 per share, while IIPR is trading at a much higher price above its book value.
Despite this, NLCP's superior<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39866180/this-cannabis-lender-is-sitting-on-a-stack-of-capital-100-dividends-meet-equity-lik"> dividend yield</a> and low debt cost make it a potentially more attractive investment for income-focused investors.
&#8220;Five operators (four public) accounted for 65% of total rental income as of 3Q24 (Curaleaf (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/curlf#NASDAQ">CURLF</a>) 23%; Cresco Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#NASDAQ">CRLBF</a>) 14%; Trulieve (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) 11%; Cannabist 9%; C3 8%); this compared with 68% in 3Q23. At IIPR, five operators accounted for 50% of rental income in 3Q24 (PharmaCann 17%; Ascend Wellness (CSE: AAWH) 11%; Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) 8%; Curaleaf 7%; Trulieve 7%),&#8221; Zuanic wrote. 
Read Next:<a href="https://www.benzinga.com/government/regulations/24/11/42235292/pharma-grade-cannabis-could-hit-walgreens-cvs-but-can-the-industry-survive-the-fda"> Pharma-Grade Cannabis Could Hit Walgreens &amp; CVS—But Can The Industry Survive The FDA?</a>

Analyst Color

Cannabis

Market Summary

Penny Stocks

REIT

Guidance

Small Cap Analysis

Small Cap

Legal

Success Stories

Markets

General

Real Estate

AAWH

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

IIPR

NLCP

TCNNF

The Price Is Right: This Weed Real Estate Stock Proves Conservative Strategies Bring Returns

Streaming giant Netflix was one of the big winners in the Golden Globe nominations. President-elect Donald Trump could be one of the losers with a film he tried to stop from premiering nominated for two awards in <a href="https://www.benzinga.com/general/entertainment/24/12/42395178/golden-globes-2025-nominations-netflix-scores-nods-for-emilia-perez-and-squid-game-comcast-lands-4-wicked-noms">Monday's announcement.</a>
What Happened: Trump <a href="https://www.benzinga.com/general/entertainment/24/04/38212867/donald-trump-biopic-gets-cannes-film-festival-premiere-heres-the-details-when-moviegoers-co">fought to have </a>"The Apprentice" blocked from movie theaters, but ultimately failed to prevent moviegoers at film festivals and in movie theaters from seeing the film which centers on his rise to power in the 1970s under mentor Roy Cohn.
While Trump's fight against the film may have kept big studios and streaming companies from pushing the film in front of consumers, it is now one of the limited number of films nominated for a 2025 Golden Globe Award.
Sebastian Stan, who played Trump in the film, was nominated for a 2025 Golden Globe in the Best Performance by a Male Actor in Motion Picture – Drama category.
Jeremy Strong, who played Cohn in the film, was also nominated for a 2025 Golden Globe in the Best Performance by a Male Actor in a Supporting Role in Any Motion Picture category.
For Stan, the nomination was one of two he received, as he was also nominated for "A Different Man" in the Best Performance by a Male Actor in Motion Picture – Musical or Comedy category.
Stan's nominations in both lead acting categories is the first for a male at the Golden Globe Awards since 2012 (Ryan Gosling).
"I never would've dreamt that I was going to be going to the Globes with both of these films," Stan <a href="https://www.vanityfair.com/hollywood/story/sebastian-stan-is-still-shaking-after-getting-two-golden-globe-nominations">told </a>Vanity Fair.
Stan highlighted that "The Apprentice" is about "one of the most famous people in the world." The actor said the film faced an uphill battle due to Trump's rejection of the movie.
"It's been hard for people to have permission to express how they feel about the movie, and today feels very gratifying in terms of having the Golden Globes recognize the film, and the work. It feels like hopefully going forward people can feel okay talking about it, and see it."
The film <a href="https://www.boxofficemojo.com/title/tt8368368/?ref_=bo_se_r_1">grossed </a>$4.0 million domestically and $8.1 million internationally in movie theaters according to BoxOfficeMojo.
Stan has never won a Golden Globe, with his only other nomination coming for "Pam &amp; Tommy" where he played Mötley Crüe drummer Tommy Lee in the limited series on Hulu.
Strong was nominated twice for the HBO series "Succession," winning one Golden Globe.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/05/38931874/trump-campaign-threatens-legal-action-over-controversial-new-biopic-about-ex-president-that">Trump Campaign Threatens Legal Action Over Controversial New Biopic About Ex-President That Received 8-Minute Ovation At Cannes: &#8216;Pure Malicious Defamation&#8217;</a>
What's Next: Stan has two chances to take home his first Golden Globe Award. For the drama motion picture category, these are the nominees:
<ul>
<li>Adrien Brody (&#8220;The Brutalist&#8221;)</li>
<li>Timothée Chalamet (&#8220;A Complete Unknown&#8221;)</li>
<li>Daniel Craig (&#8220;Queer&#8221;)</li>
<li>Colman Domingo (&#8220;Sing Sing&#8221;)</li>
<li>Ralph Fiennes (&#8220;Conclave&#8221;)</li>
<li>Sebastian Stan (&#8220;The Apprentice&#8221;)</li>
</ul>
In the motion picture musical or comedy category, these are the nominees:
<ul>
<li>Jesse Eisenberg (&#8220;A Real Pain&#8221;)</li>
<li>Hugh Grant (&#8220;Heretic&#8221;)</li>
<li>Gabriel Labelle (&#8220;Saturday Night&#8221;)</li>
<li>Jesse Plemons (&#8220;Kinds of Kindness&#8221;)</li>
<li>Glen Powell (&#8220;Hit Man&#8221;)</li>
<li>Sebastian Stan (A Different Man)</li>
</ul>
The 2025 Golden Globe Awards will air on CBS and stream on Paramount+, which are units of Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) on Jan. 5.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42351922/trump-predicted-taylor-swift-sales-would-drop-target-data-shows-over-800k-sold">Trump Predicted Taylor Swift Sales Would Drop—Target Data Shows Over 800K Sold</a></li>
</ul>
Photo: &#8220;The Apprentice,&#8221; Apprentice Produtions Ontario Inc./Profile Productions 2 APS/Tailored Films Ld. 2023, IMDb

Entertainment

Politics

PARA

PARAA

Donald Trump Tried To Block 'The Apprentice' From Movie Theaters, Film Gets 2 Golden Globe Nominations

In a report released today, Alexander Galitsa from Hauck & Aufhaeuser maintained a Buy rating on Medios AG (MEDOF – Research Report), with a price ...

Medios AG (MEDOF) Gets a Buy from Hauck & Aufhaeuser

In a report released on August 13, Matthias Maenhaut from Kepler Capital maintained a Buy rating on Medios AG (MEDOF – Research Report), with a pri...

Kepler Capital  Keeps Their Buy Rating on Medios AG (MEDOF)

In a report released yesterday, Charlotte Friedrichs from Berenberg Bank maintained a Buy rating on Medios AG (MEDOF – Research Report), with a pri...

Medios AG (MEDOF) Receives a Buy from Berenberg Bank

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medios AG (MEDOF – Research Report) and Medtronic (M...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Berenberg Bank analyst Charlotte Friedrichs maintained a Buy rating on Medios AG (MEDOF – Research Report) today and set a price target of €35.00. ...

Medios AG (MEDOF) Gets a Buy from Berenberg Bank

Medios AG (MEDOF) Receives a Buy from Hauck & Aufhaeuser

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medios AG (MEDOF – Research Report), Urogen Pharma (URGN – Resear...

Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Urogen Pharma (URGN) and Siemens Healthineers AG (OtherSEMHF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Marinus (MRNS – Research Report) and Medios AG (MEDOF – Research ...

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS) and Medios AG (OtherMEDOF)

In a report released on November 12, Matthias Maenhaut from Kepler Capital maintained a Buy rating on Medios AG (MEDOF – Research Report), with a p...

Medios AG (MEDOF) Gets a Buy from Kepler Capital

Warburg Research analyst Michael Heider maintained a Buy rating on Medios AG (MEDOF – Research Report) today and set a price target of €36.00. The ...

Comments

Medios

Medios (MEDOF) Forecast

Medios (OTC:MEDOF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga